Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $41.7778.

TEVA has been the subject of a number of recent analyst reports. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Truist Financial raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the sale, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This trade represents a 64.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Eliyahu Sharon Kalif sold 106,563 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the sale, the executive vice president directly owned 65,621 shares of the company’s stock, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 465,931 shares of company stock worth $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the stock. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $1,098,060,000. WCM Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva submitted an NDA to the FDA for ecopipam, a first-in-class candidate for pediatric Tourette syndrome, supported by positive Phase 3 data and regulatory designations that could make it the first new approved treatment in more than a decade. Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
• Positive Sentiment: Additional coverage highlighted that ecopipam’s Phase 3 results showed a statistically significant delay in relapse versus placebo, reinforcing optimism that Teva’s neuroscience pipeline could support longer-term growth. Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
• Neutral Sentiment: Teva also said it will host its second-quarter 2026 earnings call on July 29 and has posted a Q2 aide memoire, which helps set up the next major investor catalyst but does not by itself change the story. Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
• Neutral Sentiment: The Q2 2026 aide memoire was released ahead of earnings, providing investors with preparatory information rather than a new operating update. Teva Releases Q2 2026 Aide Memoire

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $31.50 on Monday. The company has a market capitalization of $36.22 billion, a PE ratio of 23.68, a P/E/G ratio of 3.29 and a beta of 0.84. The company has a 50 day simple moving average of $33.52 and a two-hundred day simple moving average of $32.23. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries has a fifty-two week low of $14.99 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Research analysts anticipate that Teva Pharmaceutical Industries will post 2.31 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.